NCT05377528View on ClinicalTrials.gov

Study of AGEN1571 in Participants With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

July 19, 2022

Primary Completion Date

December 23, 2024

Study Completion Date

December 23, 2024

Conditions
Advanced Solid Tumor
Interventions
DRUG

AGEN1571

A fully human monoclonal immunoglobulin-like transcript antagonist antibody administered intravenously.

DRUG

Balstilimab

A fully human monoclonal programmed cell death protein 1 antagonist antibody administered intravenously.

DRUG

Botensilimab

A fully human fragment crystallizable-enhanced monoclonal cytotoxic T lymphocyte antigen 4 antibody administered intravenously.

Trial Locations (6)

10029

Icahn School of Medicine at Mount Sinai, New York

34232

Florida Cancer Specialists, Sarasota

80218

Sarah Cannon Research Institute at HealthONE, Denver

90033

USC Norris Comprehensive Cancer Center, Los Angeles

02215

Dana Farber Cancer Institute, Boston

02903

Lifespan Cancer Institute, Providence

Sponsors

Lead Sponsor

Agenus Inc.
All Listed Sponsors
lead

Agenus Inc.

INDUSTRY